摘要
利福昔明(Rifaximin)是利福霉素衍生物,对多种革兰阳性、革兰阴性需氧菌和厌氧菌均有高度抗菌活性,是治疗大肠埃希菌所致旅游者腹泻的一种新药.口服不易被肠道吸收,在肠道内有较高浓度,全身不良反应轻微是其特点.近年来利福昔明在肝性脑病、肠内胀气及肠道气体相关性疾病、憩室病、肠内细菌过度生长、炎症性肠病(IBD)以及幽门螺杆菌感染(H pylori)的根除等疾病治疗中应用日趋广泛并取得了较好疗效.
Rifaximin, a derivative of rifamycin, has high antibacterial activity on various kinds of Grampositive and -negative aerobes and anaerobes, and it is a new drug in the treatment of giardiasis Rifaximin is not easy to be absorbed after oral administration, and mild systemic adverse reaction is the main characteristic. Recently, Rifaximin has been widely and effectively used in the therapy of many diseases related to intestinal bacterial infection such as hepatic encephalopathy, diverticular disease, overgrowth of intestinal bacteria, inflammatory bowel disease （IBD） and H pylori infection. The above advances were reviewed in the present article.
出处
《世界华人消化杂志》
CAS
北大核心
2007年第13期1457-1462,共6页
World Chinese Journal of Digestology
关键词
利福昔明
憩室病
肠内细菌过度生长
炎症性肠病
幽门螺杆菌
Rifaximin
Diverticular disease
Over-growth of intestinal bacteria
Inflammatory boweldisease
Helicobacter pylori
